Stereotactic body radiation therapy for an unresectable FGF23-secreting tumor of the cervical spine: A case report and literature review

Kathryn Hockemeyer; Juhi M Purswani; Joseph K Kim; Babak Givi; Elcin Zan; Donato Pacione; Maksim Shapiro; Ilya Laufer; Jill B Feffer; Joshua S Silverman

Stereotactic body radiation therapy for an unresectable FGF23-secreting tumor of the cervical spine: A case report and literature review

J Radiosurg SBRT. 2022;8(4):321-324.

Authors

Affiliations

¹ Department of Radiation Oncology, NYU Langone Health and Grossman School of Medicine, New York, NY, USA.
² Department of Head and Neck Surgery, NYU Langone Health and Grossman School of Medicine, New York, NY, USA.
³ Department of Radiology, NYU Langone Health and Grossman School of Medicine, New York, NY, USA.
⁴ Department of Neurosurgery, NYU Langone Health and Grossman School of Medicine, New York, NY, USA.
⁵ Division of Interventional Neuroradiology, Department of Radiology, NYU Langone Health and Grossman School of Medicine, New York, NY, USA.
⁶ Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, NYU Langone Health and Grossman School of Medicine, New York, NY, USA.

PMID: 37416336
PMCID: PMC10322171

Abstract

We present the case of a 65-year-old male with tumor-induced osteomalacia (TIO) caused by an FGF23-secreting phosphaturic tumor of C2 treated definitively with stereotactic body radiation therapy (SBRT) and kyphoplasty. The patient exhibited notable reduction in FGF23 6 weeks following radiotherapy. He also received a dose of the FGF23 monoclonal antibody, burosumab. We discuss the case with emphasis on radiation in the management of TIO. This case demonstrates SBRT as a well-tolerated local treatment option for the management of unresectable FGF23-producing tumors.

Keywords: FGF-23; SBRT; kyphoplasty; tumor-induced osteomalacia.